Share ownership Akeso, Inc.

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:14 17/03/2026 pm IST			5-day change	1st Jan Change
117.50 ^HKD	+0.77%		+13.31%	+3.98%

05/03	Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral	MT
05/03	Akeso, Inc. Presents Long-Term Phase II Results For Cadonilimab In Recurrent Or Metastatic Cervical Cancer	CI

Share class: Akeso, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	89,75,75,176	66,83,35,039 ( 74.46 %)	0	74.46 %

Major shareholders: Akeso, Inc.

Name	Equities	%	Valuation
Xia Yu Family 6.036 %	5,55,99,042	6.036 %	760 M $
Green Court Capital Management Ltd. 4.683 %	4,31,40,669	4.683 %	590 M $
Li Bai Yong Family 4.151 %	3,82,38,554	4.151 %	523 M $
Zhang Peng Family 3.529 %	3,25,08,065	3.529 %	444 M $
Zhongmin Wang 3.446 %	3,17,42,881	3.446 %	434 M $
Michelle Xia 2.823 %	2,60,00,000	2.823 %	355 M $
Baiyong Li 1.323 %	1,21,84,640	1.323 %	167 M $
Wang Zhong Min Family 1.227 %	1,13,06,442	1.227 %	155 M $
HuaAn Fund Management Co., Ltd. 1.227 %	1,13,04,000	1.227 %	154 M $
Zhong Ou Asset Management Co., Ltd 1.162 %	1,07,04,000	1.162 %	146 M $
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	22.54%
Institutional	15.66%
Unknown	61.8%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	22.54%
China	9.94%
Hong Kong	5.15%
United States	0.23%
United Kingdom	0.07%
Singapore	0.05%
New Zealand	0.04%
Luxembourg	0.03%
France	0.03%
Ireland	0.03%
Norway	0.02%
Netherlands	0.02%
Japan	0.01%
Switzerland	0.01%

Based on 1000 largest holdings

Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.

Employees

3,529

Sector

Biotechnology & Medical Research

Calendar

26/03 - Earnings release - Annual 2025

More about the company